BeVigilant OraFusion System
Commercial- Indications
- Oral cancer
Company intelligence / Profile preview
The BeVigilant OraFusion System has demonstrated significant clinical benefits for early detection of oral cancers using a saliva-based point-of-care test that identifies specific protein biomarkers. Ongoing clinical results indicate improved patient outcomes through earlier intervention. The system has received FDA Breakthrough Device Designation and awaits full regulatory approval in the U.S., while already being used internationally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vigilant Biosciences.